These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 36183210)

  • 1. Systematic review and meta-analysis of interleulin-6 inhibitors in reducing mortality for hospitalized patients with COVID-19.
    Alegre-Del-Rey EJ; Fénix-Caballero S; Salmerón-Navas FJ; Gil-Sierra MD; Sierra-Sánchez JF; Díaz-Alersi Rosety RL
    Farm Hosp; 2022 May; 46(3):166-172. PubMed ID: 36183210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.
    Sweeney DA; Lobo SM; Póvoa P; Kalil AC
    Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.
    Peng J; Fu M; Mei H; Zheng H; Liang G; She X; Wang Q; Liu W
    Rev Med Virol; 2022 May; 32(3):e2295. PubMed ID: 34558756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Boppana TK; Mittal S; Madan K; Mohan A; Hadda V; Guleria R
    Monaldi Arch Chest Dis; 2022 Feb; 92(4):. PubMed ID: 35130679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.
    Godolphin PJ; Fisher DJ; Berry LR; Derde LPG; Diaz JV; Gordon AC; Lorenzi E; Marshall JC; Murthy S; Shankar-Hari M; Sterne JAC; Tierney JF; Vale CL
    PLoS One; 2022; 17(7):e0270668. PubMed ID: 35802687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis.
    Zeraatkar D; Cusano E; Martínez JPD; Qasim A; Mangala S; Kum E; Bartoszko JJ; Devji T; Agoritsas T; Guyatt G; Izcovich A; Khamis AM; Lamontagne F; Rochwerg B; Vandvik P; Brignardello-Petersen R; Siemieniuk RAC
    BMJ Med; 2022; 1(1):e000036. PubMed ID: 36936570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
    Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
    Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
    Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
    Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.
    Lim PC; Wong KL; Rajah R; Chong MF; Chow TS; Subramaniam S; Lee CY
    Daru; 2022 Jun; 30(1):211-228. PubMed ID: 35084705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Swets MC; Moss RJ; Kor F; Hilarius D; Moes DJAR; Berkhout WE; van den Toorn LM; van den Oever NCG; de Valk R; Rosendaal FR; Hunfeld N; Groeneveld GH; de Boer MGJ
    Int J Infect Dis; 2023 Apr; 129():57-62. PubMed ID: 36738957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
    Sivapalasingam S; Lederer DJ; Bhore R; Hajizadeh N; Criner G; Hosain R; Mahmood A; Giannelou A; Somersan-Karakaya S; O'Brien MP; Boyapati A; Parrino J; Musser BJ; Labriola-Tompkins E; Ramesh D; Purcell LA; Gulabani D; Kampman W; Waldron A; Ng Gong M; Saggar S; Sperber SJ; Menon V; Stein DK; Sobieszczyk ME; Park W; Aberg JA; Brown SM; Kosmicki JA; Horowitz JE; Ferreira MA; Baras A; Kowal B; Thomas DiCioccio A; Akinlade B; Nivens MC; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM
    Clin Infect Dis; 2022 Aug; 75(1):e380-e388. PubMed ID: 35219277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
    Liu M; Wang H; Liu L; Cui S; Huo X; Xiao Z; Zhao Y; Wang B; Zhang G; Wang N
    Front Immunol; 2022; 13():1046352. PubMed ID: 36389759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab in the treatment of COVID-19-a meta-analysis.
    Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
    QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.
    Merchante N; Cárcel S; Garrido-Gracia JC; Trigo-Rodríguez M; Moreno MÁE; León-López R; Espíndola-Gómez R; Alonso EA; García DV; Romero-Palacios A; Pérez-Camacho I; Gutiérrez-Gutiérrez B; Martínez-Marcos FJ; Fernández-Roldán C; Pérez-Crespo PMM; Caño AA; León E; Corzo JE; de la Fuente C; Torre-Cisneros J
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0210721. PubMed ID: 34902262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.